Cubist Pharmaceuticals (CBST) Posts Quarterly Results
Cubist Pharmaceuticals (CBST) posted its quarterly earnings results on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of $0.31 by $0.20. The company’s quarterly revenue was up 31.6% on a year-over-year basis.
On a related note, analysts at Bank of America (NYSE: BAC) reiterated a “buy” rating on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday, January 11st. Also, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Cubist Pharmaceuticals in a research note to investors on Tuesday, January 10th. They now have a $48.00 price target on the stock.
Cubist Pharmaceuticals (CBST) traded down 1.51% on Thursday, hitting $40.40. Cubist Pharmaceuticals (CBST) has a 52-week low of $20.95 and a 52-week high of $42.10. The stock has a 50-day moving average of $39.19 and a 200-day moving average of $36.15. The company has a market cap of $2.487 billion and a price-to-earnings ratio of 71.22.
Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. Cubist’s owns CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). During the year ended December 31, 2009, this product was used in the treatment of more than an estimated 880,000 patients. In December 2009, the Company acquired Calixa Therapeutics Inc.
Paula Deen says she has diabetes, will endorse pharmaceutical company
Paula Deen made waves this week when she announced that she’d be diagnosed with Type 2 diabetes.
Deen isn’t just any other American, though. She hosts a cooking show, renowned for its liberal use of fats, sugars and especially butter. And instead of announcing the diabetes to say she was going to change her ways, Deen went in a different direction.
She announced she was becoming a paid spokeswoman for pharmaceutical giant Novo Nordisk AS, which makes diabetes drugs such as Victoza. Deen said she was diagnosed three years ago but kept the matter private — seemingly until she could find a way to turn the diagnosis into a financial windfall.
Deen’s behavior has outraged some, particularly those who think lifestyle changes are important for dealing with, and potentially reversing, the effects of Type 2 diabetes.
Suzanne Vranica, a reporter for The Wall Street Journal who’s examined Deen’s announcement, said consumers think this Deen’s behavior is a complete sham.
“I think the real reason we’re seeing this problem is because she’s known for so long she’s had these problems and she’s done nothing in terms of her show and her books to promote a healthy lifestyle, which is needed when you’re combatting this sort of diabetes,” she sid.
Celebrity Chef Anthony Bourdain didn’t hold back in his criticisms either.
“Thinking of getting into the leg-breaking business, so I can profitably sell crutches later,” he tweeted.
Vranica described Deen’s problem as talking out of both sides of her mouth.
“The real crux of the problem is she’s basically tip-toed around this question about, “Well, on your show, will you now begin to promote healthier lifestyles.’ Although her spokespeople have said she’s in discussions to do that, it’s been slow going,” Vranica said.
They also point out that her son’s new show will feature healthier food.
But no matter how it turns out, Vranica said, there will be real ramifications for Deen and her brand because of this.
“Her brand was soaring up until now. What will happen to her book sales? Will people tune out,” Vranica said. “Given the reaction we’ve seen on social media sites, I anticipate there’s definitely going to be some financial fallout for her.”
China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End
China Health Resource, Inc. CHRI
+68.18% , announced
today that its pharmaceutical grade Gastrodia based product line has experienced double digit sales growth in 2011 with increased profit margins. The Gastrodia product line is expected to generate an estimated 50 million yuan (US$8 million) of revenue in 2011 for CHRI. The strength of the Company’s core product lines and rapid growth in newer higher margin products is expected to drive record revenue and earnings. The Company will confirm the disclosed preliminary figures at the time of disclosure of the annual report for 2011.
China Health Resource, Inc. entered into an exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan in April 2011. The agreement gives CHRI leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of Gastrodia (also known as Tianma). Gastrodia currently retails for about 250~1,000 yuan/kg (US$38~150/kg) and is considered one of China’s highest value TCM drugs available in the market. This exclusive arrangement for the supply of Gastrodia is expected to generate an estimated combined total of 50 million yuan (US$8 million) of revenue for CHRI over the 2011-2012 period.
“Our core strength in establishing DAR as a standard has resulted in an enviable growth in revenues and margins in our DAR product line and the Gastrodia product line is the natural progression of CHRI product on large global markets with higher profit margins. We expect this will be reflected in our 2011 year in both revenues and earnings” stated Jiayin Wang, Chairman and CEO of CHRI.
“Gastrodia is an important herb with high margins and we expect it will add a significant contribution to our top and bottom line. As a TCM ingredient, it has pain relieving and anti-inflammatory properties, and it is used in the treatment of severe headaches and nervous fatigue. In time, we expect Gastrodia to have the same standard of acceptance as GAP DAR.” added Jiayin Wang.